biostudies-literatureMoore CBNational Institute of Allergy and Infectious DiseasesNICHD NIH HHSNIAID NIH HHSNational Institute of Mental HealthNational Institutes of HealthNational Institute of Child Health and Human Developmente191-e200https://www.ebi.ac.uk/biostudies/studies/S-EPMC12087306biostudies-literatureUnknown12(3)<h4>Background</h4>Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral cabotegravir and rilpivirine followed by a combination of long-acting cabotegravir and long-acting rilpivirine in virologically suppressed adolescents with HIV.<h4>Methods</h4>The IMPAACT 2017/MOCHA study is a phase 1/2, multicentre, open-label, non-comparative, dose-finding trial being conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA. In cohort 2 of this study, adolescents (aged 12-18 years; weight ≥35 kg) with HIV and no serious comorbidities who were receiving stable combination ART with confirmed virological The lancet. HIVSafety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.PMC12087306UM1 AI068632UM1 AI106716UM1AI068616UM1 AI069536HHSN275201800001IUM1AI106716U01 AI069530UM1 AI068616HHSN275201800001CUM1AI068632UM1 AI069399UM1 AI069530Zabih SWhitson KHan KMarzinke MAHuang JLin YWBuisson SKorutaro VPaul MEViolari AVan Eygen VWard SVan Solingen-Ristea RMCrauwels HMasheto GMoye JHGaur AHWhitton MBest BMHanley SAurpibul LPatel FLowenthal EDAgwu ALCapparelli EVTownley EMcCoig CHarrington CMCheung SYAFord SLOunchanum PVandermeulen KMoore CBHeckman BKrotje CMilligan RYin DEDeprez IIMPAACT 2017 Collaborators for the IMPAACT 2017 TeamBaltrusaitis KRoberts GCollins JWfalseSafety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.<h4>Background</h4>Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral cabotegravir and rilpivirine followed by a combination of long-acting cabotegravir and long-acting rilpivirine in virologically suppressed adolescents with HIV.<h4>Methods</h4>The IMPAACT 2017/MOCHA study is a phase 1/2, multicentre, open-label, non-comparative, dose-finding trial being conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA. In cohort 2 of this study, adolescents (aged 12-18 years; weight ≥35 kg) with HIV and no serious comorbidities who were receiving stable combination ART with confirmed virological 2025-01-01T00:00:00Z2025 Mar2026-07-16T23:23:30.39Z2026-07-12T03:11:02.547ZS-EPMC120873064004992410.1016/S2352-3018(24)00344-810.1016/s2352-3018(24)00344-8